|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
19,560,000 |
Market
Cap: |
161.37(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.89 - $14.75 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 21.3 |
Insider 3/6 Months : 21.9 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Solid Biosciences is engaged in curing Duchenne muscular dystrophy (Duchenne), a genetic muscle-wasting disease predominantly affecting boys. SGT-001 and SGT-003 are Co.'s gene transfer candidates. SGT-001 and SGT-003 are designed to address the underlying genetic cause of Duchenne by delivering a synthetic transgene that produces dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. Co.'s SGT-001 and SGT-003 vectors are derived from a naturally occurring, non-pathogenic virus called adeno-associated virus, which were selected for their ability to enter skeletal, diaphragm and cardiac muscle tissues.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
4,314,873 |
4,314,873 |
4,314,873 |
Total Buy Value |
$0 |
$23,861,248 |
$23,861,248 |
$23,861,248 |
Total People Bought |
0 |
2 |
2 |
2 |
Total Buy Transactions |
0 |
2 |
2 |
2 |
Total Shares Sold |
462 |
35,539 |
35,539 |
37,990 |
Total Sell Value |
$4,772 |
$126,957 |
$126,957 |
$144,031 |
Total People Sold |
1 |
7 |
7 |
8 |
Total Sell Transactions |
1 |
9 |
9 |
13 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Morris Carl Ashley |
Chief Scientific Officer |
|
2022-03-14 |
4 |
AS |
$1.10 |
$24,932 |
D/D |
(22,665) |
255,209 |
|
-30% |
|
Ganot Ilan |
CEO & President |
|
2022-02-10 |
4 |
AS |
$1.12 |
$519 |
I/I |
(463) |
2,518 |
|
-52% |
|
Koppel Adam |
Director |
|
2021-03-23 |
4 |
A |
$5.75 |
$4,999,999 |
I/I |
869,565 |
7,929,918 |
|
- |
|
Edelman Joseph |
Director |
|
2021-03-23 |
4 |
B |
$5.75 |
$14,999,996 |
I/I |
2,608,695 |
13,412,552 |
2.25 |
-50% |
|
Shah Rajeev M. |
Director |
|
2021-03-19 |
4 |
B |
$5.75 |
$12,688,439 |
I/I |
2,206,685 |
10,916,567 |
2.25 |
-52% |
|
Morris Carl Ashley |
Chief Scientific Officer |
|
2021-03-12 |
4 |
AS |
$8.84 |
$206,947 |
D/D |
(23,398) |
275,602 |
|
-69% |
|
Schneider Joel Solomon Zev |
Chief Operating Officer |
|
2021-03-12 |
4 |
AS |
$8.84 |
$206,920 |
D/D |
(23,398) |
268,774 |
|
-69% |
|
Ganot Ilan |
CEO & President |
|
2021-02-12 |
4 |
S |
$7.66 |
$3,501 |
I/I |
(457) |
3,026 |
|
50% |
|
Ziolkowski Jennifer Lynn |
CFO, Treasurer & Asst. Secy |
|
2021-01-28 |
4 |
S |
$6.14 |
$21,327 |
D/D |
(3,473) |
335,636 |
|
37% |
|
Schneider Joel Solomon Zev |
Chief Technology Officer |
|
2021-01-28 |
4 |
S |
$6.14 |
$21,145 |
D/D |
(3,443) |
292,172 |
|
37% |
|
Morris Carl Ashley |
Chief Scientific Officer |
|
2021-01-28 |
4 |
S |
$6.14 |
$21,238 |
D/D |
(3,459) |
299,000 |
|
37% |
|
Ganot Ilan |
CEO & President |
|
2021-01-28 |
4 |
S |
$6.14 |
$65,776 |
D/D |
(10,713) |
1,199,821 |
|
37% |
|
Ziolkowski Jennifer Lynn |
CFO, Treasurer & Asst. Secy |
|
2021-01-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,500 |
339,109 |
|
- |
|
Schneider Joel Solomon Zev |
Chief Technology Officer |
|
2021-01-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,500 |
295,615 |
|
- |
|
Morris Carl Ashley |
Chief Scientific Officer |
|
2021-01-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,500 |
302,459 |
|
- |
|
Ganot Ilan |
CEO & President |
|
2021-01-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,500 |
1,210,534 |
|
- |
|
Kolchinsky Peter |
Director |
|
2020-12-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
8,709,882 |
|
32% |
|
Edelman Joseph |
10% Owner |
|
2020-12-10 |
4 |
A |
$3.70 |
$15,000,000 |
I/I |
4,054,054 |
10,803,857 |
|
- |
|
Arnold Matthew Bennett |
Director |
|
2020-12-10 |
4 |
A |
$3.70 |
$1,599,998 |
D/D |
432,432 |
3,933,429 |
|
- |
|
Ganot Ilan |
CEO & President |
|
2020-12-10 |
4 |
A |
$3.70 |
$100,000 |
D/D |
27,027 |
1,175,034 |
|
- |
|
Smith Ian F |
Director |
|
2020-12-10 |
4 |
A |
$3.70 |
$999,999 |
D/D |
270,270 |
270,270 |
|
- |
|
Shah Rajeev M. |
Director |
|
2020-12-10 |
4 |
A |
$3.70 |
$18,271,643 |
I/I |
4,938,282 |
8,709,882 |
|
- |
|
Koppel Adam |
Director |
|
2020-12-10 |
4 |
A |
$3.70 |
$11,799,999 |
I/I |
3,189,189 |
7,060,353 |
|
- |
|
Ultragenyx Pharmaceutical Inc. |
10% Owner |
|
2020-10-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,825,797 |
|
157% |
|
Ganot Ilan |
CEO & President |
|
2020-08-13 |
4 |
S |
$2.44 |
$730 |
I/I |
(299) |
3,483 |
|
-172% |
|
129 Records found
|
|
Page 3 of 6 |
|
|